Novo Nordisk, Eli Lilly rise after Pfizer scraps obesity pill
Pfizer will stop developing a weight-loss pill after it was linked to liver injury in one patient enrolled in a clinical trial, giving a boost to Novo Nordisk and Eli Lilly, which are fighting to keep their place at the center of the weight-loss drug market.
Pfizer’s once-daily pill, called danuglipron, won’t advance into the final stage of testing. Pfizer was flat on the news while Novo and Lilly rose in early trading.
Novo, which makes Ozempic and Wegovy, and Lilly, which makes Zepbound and Mounjaro, brought in over $40 billion in revenue from GLP-1 drugs in 2024. Meanwhile, the race to make the next blockbuster weight-loss drug is heating up.
Novo, which makes Ozempic and Wegovy, and Lilly, which makes Zepbound and Mounjaro, brought in over $40 billion in revenue from GLP-1 drugs in 2024. Meanwhile, the race to make the next blockbuster weight-loss drug is heating up.